Compare · DFTX vs MO
DFTX vs MO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Altria Group Inc. (MO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $121.42B, about 50.9x DFTX ($2.39B).
- Over the past year, DFTX is up 232.6% and MO is up 22.5% - DFTX leads by 210.1 points.
- DFTX has been more active in the news (10 items in the past 4 weeks vs 5 for MO).
- MO has more recent analyst coverage (19 ratings vs 4 for DFTX).
- Company
- Definium Therapeutics Inc.
- Altria Group Inc.
- Price
- $21.89+6.81%
- $72.64+6.49%
- Market cap
- $2.39B
- $121.42B
- 1M return
- +15.85%
- +10.09%
- 1Y return
- +232.60%
- +22.50%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 5
- Recent ratings
- 4
- 19
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest DFTX
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form DEFA14A filed by Definium Therapeutics Inc.
- SEC Form DEF 14A filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
- Stifel initiated coverage on Definium Therapeutics with a new price target
- Piper Sandler initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Latest MO
- SEC Form 10-Q filed by Altria Group Inc.
- Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altria Reports 2026 First-Quarter Results; Reaffirms Full-Year Guidance
- Altria Celebrates America by Investing in Our Growers, Communities, Employees and Iconic Brands
- Altria to Host Webcast of 2026 First-Quarter Results
- SEC Form DEFA14A filed by Altria Group Inc.
- SEC Form DEF 14A filed by Altria Group Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Altria Group Inc.
- on! PLUS™ Expands Nationwide Retail Availability
- SVP, Chief HR Off. & CCO Whitaker Charles N. sold $1,885,718 worth of shares (27,908 units at $67.57), decreasing direct ownership by 13% to 180,869 units (SEC Form 4)